Literature DB >> 79251

Immunobiology of the graft-versus-host reaction. I. Symptoms of graft-versus-host disease in mice are preceded by delayed-type hypersensitivity to host histocompatibility antigens.

E A Wolters, R Benner.   

Abstract

During initiation of an acute graft-versus-host reaction by injection of C57BL/Rij spleen cells into lethally irradiated (C57BL/Rij X CBA/Rij)F1 hybrid mice, a state of delayed-type hypersensitivity (DTH) against host histocompatibility (H) antigens occurs. This was demonstrated by means of transfer of host spleen and lymph node cells into C57BL/Rij recipients, which received a challenge with CBA/Rij spleen cells. Initiation and transfer of the graft-versus-host-related DTH reactivity was highly dependent on Thy-1.2+ cells. The development of DTH reactivity started between 8 and 24 hr after semiallogeneic spleen cell transplantation and increased during the days thereafter. In the spleen maximal DTH reactivity was found on day 4, whereas in the lymph nodes maximal reactivity occurred on day 5 after irradiation and reconstitution. Thereafter, the reactivity decreased until there was no further DTH reactivity demonstrable on day 13. The specificity of the DTH reactivity for host H antigens was proved by no reactivity to a challenge of DBA/2 and Swiss spleen cells, which are H-2-incompatible with CBA cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 79251     DOI: 10.1097/00007890-197807010-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Restricted recognition of H-2 subregion coded alloantigens in delayed-type hypersensitivity.

Authors:  A T Bianchi; H Bril; L M Hussaarts-Odijk; R Benner
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

2.  Increased incidence of transient homogeneous immunoglobulins in irradiated and reconstituted C57BL/KaLwRij mice treated with 2'-deoxyguanosine.

Authors:  T W van den Akker; A P Gillen; H Bril; R Benner; J Radl
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.